Access, despite the availability of quality treatment, care and prevention services (e.g. PrEP), is often limited by the prices, i.e. the affordability of medications, diagnostics, and other health interventions. Access to affordable and quality medicines are essential for the right to health of each individual affected by HIV and AIDS, TB, and viral hepatitis. At the community and public health level, accessing affordable and quality medicines is essential for reducing transmission rates and ending all three pandemics as public health threats by 2030. Building on the activities of the 2018-2021 strategic period, AAE will continue to support strengthening the capacities of our member organisations in the 2022-2026 strategic period, in order to improve access via making quality treatment, diagnostics, and prevention methods affordable.
